Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
Pegfilgrastim is a Pegylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue Filgrastim
Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line
Stringent regulatory environments can make OEMs reluctant to change processes and materials for approved medical devices
Patni brings over 25 years of distinguished experience in the pharmaceutical industry
Sigachi's entry into the coatings market is strategically timed to capitalize on the industry's growth potential
AGEasy has made significant strides in addressing the pressing health concerns of seniors in India
The company recorded sales of Rs. 1,129 crore for the fiscal year ended June 30, 2024,
Coveris’ security labels also work seamlessly with self-checkouts where around 80% of retail sales now typically occur
Subscribe To Our Newsletter & Stay Updated
